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Global developmental delay (GDD) and intellectual disability (ID) are 
both defined by delays or deficits in at least two domains of function, 
with onset during the developmental period. Typically, the term 
GDD is reserved for children ˂5 years of age, reflecting the challenges 
of formalised testing in young children. In contrast, a diagnosis of ID 
reflects deficits in cognitive function and a broad range of adaptive 
behaviours.[1] These two groups of disorders may be grouped under 
the umbrella term intellectual developmental disorders  (IDD).[2] 
These disorders may be secondary to an external insult to the 
developing brain or primary, reflecting an early developmental 
difference. The focus of this approach is on the investigation of what 
may be defined as the IDD group of disorders, with the exclusion 
of the primary motor developmental disorders (such as cerebral 
palsy) and children presenting with progressive neurological disease 
or neuroregression, for whom a different diagnostic approach is 
indicated. The prevalence of IDD in South Africa (SA) is not well 
documented, but worldwide prevalence data suggest that 1 - 2% of 
the population may have an intellectual disability, with a prevalence 
of 2 - 5% for GDD.[3] The real extent of the impact on function 
may be much greater, with population studies of early childhood 
development in a broad sample of 3 - 4-year-old children in 35 low- 
and middle-income countries (LMIC) finding that approximately 
a third failed to meet the expected cognitive and socioemotional 
milestones.[4] A study in rural SA found a minimum prevalence of ID 
in children of 3.56%.[5] 
In SA, IDD may more commonly be caused, or further impacted 
on, by secondary exposures than in higher-income countries. These 
may include contributing factors such as prenatal alcohol exposure,[6] 
congenital infections and HIV-related developmental disorders,[7] 
which have been well documented as major contributors to the loss 
of developmental potential in SA children. There is, however, no 
reason to expect that primary genetic disorders of development are 
less common in SA than in better-resourced countries. Establishing 
the contributing aetiology(ies) or making a specific diagnosis in a 
child with IDD has numerous advantages. These include providing 
information on natural history and prognosis, avoiding additional 
costly and unnecessary investigations, refining treatment options, 
providing diagnosis-specific health surveillance and support, as well 
as providing information on recurrence risk for families.[8] There 
is also good evidence to support the substantial value to parents of 
having a ‘name’ for their child’s challenges.[9] In the context of resource 
rationing in all health systems, but particularly the public healthcare 
system, the reality of the costs of specific diagnostic investigations 
has to be balanced with their intrinsic and comparative value to other 
investigations in terms of diagnostic yield and clinical use. 
Assessment of the child with an 
intellectual developmental disorder
A comprehensive history and a thorough clinical examination are 
essential to make a diagnosis and to plan and interpret further 
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special investigations that yield more diag-
nostic results when directed in this way.[10] 
In parti cular, attention should be given to 
taking a complete pregnancy and birth/
perinatal history, including teratogen and 
conge ni tal infection exposures, a three-gene-
ration family history (which should include 
direct questioning about pregnancy loss and 
other neurological and neurodevelopmen-
tal pheno types), as well as documenting 
details of the course of the child’s health, 
growth and development up to the time 
of evaluation. Physical examination should 
include charting all growth parameters 
(including head circumference), noting any 
dysmorphic features, a full systemic exami-
nation, a detailed neurological examination 
and develop mental/cognitive assessment. 
Hearing screening should always be consi-
dered and vision assessed.[11] Studies have 
shown that in up to a third of patients, a 
diagnosis can be reached or strongly sus-
pected based on history and examination 
alone.[10]
This clinical process should yield three 
groups of patients. The first group includes 
those in whom a clinical diagnosis is made 
and investigations can be specifically tailor-
ed to confirm the diagnosis or investigate 
comorbidities, such as Down syndrome. 
There is a second group in whom the initial 
assessment leads to a suspected or possible 
diagnosis, e.g. a developmentally delayed 
child in whom findings of coarse features 
and organomegaly suggest a storage disor-
der. For this group of children, investigations 
will again be directed by clinical reasoning, 
but can be staged and directed by clinical 
context. The third group of children have 
unexplained IDD. In this group no spe-
cific clues to aetiology are evident, and a 
broader approach to further investigations 
is indicated.[11] Fig. 1 illustrates a suggested 
approach to seeking a diagnosis in SA child-
ren with IDD.
Investigations in 
unexplained intellectual 
developmental disorders
Chromosomal abnormalities
Current international guidelines recommend 
chromosomal microarray (CMA) testing for 
chromosomal imbalance as the first investigation 
in unexplained ID or GDD.[3,8,11,12] The diag-
nostic detection rate of CMA is reported as 
8 - 20%. This replaces the more traditional, 
but low-resolution, karyotype chromosomal 
analysis, which has a detection rate of ~3%, if 
the common aneuploidies are excluded.[13,14] 
In general, higher detection rates are found 
in children who have additional features 
of atypical growth, structural congenital 
abnormalities, sensory impairments and/or 
dysmorphic features. It should be remem-
bered, though, that CMA will not determine 
mechanism of dosage imbalance or detect 
chromosomal rearrangements that do 
not result in a net gain or loss of genetic 
material, and the resolution is limited 
depending on the specific CMA used.[13] 
Conventional karyotype and supplementary 
cytogenetic techniques, such as fluorescence 
in situ hybridisation (FISH), retain a place 
in confirmation of certain CMA results, in 
determination of mechanism of chromosome 
imbalances, such as Down syndrome (which 
may inform recurrence risks), and in some 
cases of recurrent pregnancy loss. Multiplex 
ligation-dependent probe amplification 
(MLPA) is also a molecular technique 
designed to detect chromosomal imbalances. 
Commercial kits targeting areas of the 
genome well described to be prone to loss 
or gain and associated with developmental 
disorders are available. Although less costly 
individually, performing a karyotype and 
two MLPA kits are similar in cost to CMA, 
which has a much better resolution and 
hence diagnostic yield. Therefore, although 
CMA is the preferred test for chromosomal 
abnormalities, MLPA may have a place 
where the resources required for CMA are 
not available. 
Fragile X syndrome testing
The clinical presentation of fragile X syn-
drome (FXS) can be nonspecific, particu-
larly in young children, and in the past has 
prompted routine testing for FMR1 expan-
sion mutations in IDD, mostly in boys, 
although the disorder also presents in girls. 
A systematic review and meta-analysis pub-
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Fig. 1. Flow chart for investigating intellectual developmental disorders in children. (TFTs = thyroid 
function tests; CMA = chromosomal microarray; MLPA = multiplex ligation-dependent probe 
amplification; pos = positive; neg = negative; MRI = magnetic resonance imaging; CT = computed 
tomography; FX = fragile X; CK = creatine kinase.)
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lished in 2014 found the population frequency of full expansions to 
be 1.4/10 000 for males and 0.9/10 000 for females.[15] Although still 
commonly performed as a first-line investigation in boys, it may not 
be cost effective in all children with IDD, but is definitely indicated 
in those with a suggestive family history or clinical features. Other 
X-linked single-gene disorders are collectively more common than 
FXS, and in situations where X-linked inheritance is possible, addi-
tional genetic testing approaches need to be considered, as discussed 
below.[8]
Neuroimaging 
As most young children (especially those with IDD) need an 
anaesthetic or sedation for neuroimaging, its role as a first-line 
investigation remains controversial in unexplained IDD. Children who 
have associated epilepsy, particularly if there is a focal element, those 
with neurological signs and those with a significant disturbance in 
head growth, should be considered for magnetic resonance imagimg 
(MRI) or, if not available, a computed tomography (CT) scan early 
in their diagnostic investigations.[11] For most children with non-
progressive ID or GDD without additional neurological symptoms or 
physical findings, neuroimaging has a relatively low diagnostic yield. 
Metabolic investigations
There is universal agreement that thyroid function tests should 
be included in the initial investigation of unexplained IDD, as 
hypothyroidism is amenable to treatment and testing is accessible 
and affordable. Indications for additional metabolic screening and 
testing in the absence of clinical clues are not quite as consistent. 
Some guidelines advocate for this approach in all children with 
IDD, with particular emphasis on disorders potentially amenable 
to treatment.[8,10] Such investigations are costly and, given that there 
is usually some clinical indication to suggest a metabolic disorder, 
it may be reasonable to reserve these for selected cases, especially 
in resource-constrained environments. A retrospective study by 
Hart et al.[14] showed that no metabolic disorders were identified in 
children for whom early developmental impairment was the only 
clinical feature. It does, however, underscore the attention to detail 
that needs to be elicited on history-taking and examination, such 
as parental consanguinity, a history of a fluctuant course, episodes 
of deterioration triggered by stress or additional clinical features 
suggesting a metabolic aetiology. 
Tests that are most often included in a broad screen for metabolic 
aetiology of developmental delay include plasma lactate, ammonia, 
urine amino and organic acids and serum amino acids, along 
with routine biochemistry, such as urea and electrolytes and liver 
function tests.[3,4] Other guidelines include serum homocysteine 
and acylcarnitines, as well as oligosaccharides, glycosaminoglycans 
and purines and pyrimidines in the first-line screening, with other 
metabolic tests being driven by clinical indication.[8] 
Nonspecific screening tests 
General screening tests, such as full blood count, urea and 
electrolytes, iron studies and lead levels, are often included in the 
initial investigation of IDD, but there is little evidence to suggest that 
they add value unless clinically directed, and may be omitted without 
compromising care.[14] Creatinine kinase level determination is 
recommended in some guidelines as the screening test for Duchenne 
muscular dystrophy (DMD) in young boys with GDD, recognising 
that GDD may precede signs of muscle disease in some of these 
boys. As the test is inexpensive and carries significant management 
and counselling implications for the child and family, it is worth 
considering in this subgroup of children. 
Genetic testing strategies for single-
gene disorders
In children with IDD in whom a genetic diagnosis is suspected, it is 
important to select the most appropriate testing strategy and to be 
aware of the limitations of the test. Genetic mutations can be detected 
by various techniques. Targeted mutation testing for a single mutation 
or a limited number of mutations in a particular gene still retains a 
place as a cost-effective strategy for populations that have founder 
mutations or for disorders that are commonly caused by a small 
number of mutations. These strategies are, however, inherently limited 
to the ability to include, but not exclude, a diagnosis. Sanger sequencing 
of a specific gene has long been considered the gold standard for 
testing for single-gene disorders, but is not able to detect deletions or 
duplications and becomes expensive if sequential testing of a number 
of genes that may cause the phenotype in question. Next-generation 
sequencing (NGS) technologies allow rapid, reliable and simultaneous 
testing of multiple genes. Gene-panel testing using NGS, in which 
multiple genes implicated in disorders for which there is clinical and 
genetic heterogeneity and overlap, has replaced sequential single-gene 
testing as a quicker and more cost-effective strategy.[16] 
In IDD, a large number of genes are implicated, with many as yet 
possibly undiscovered. This makes testing challenging, unless there 
are clinical clues to direct the clinician towards a single gene or panel 
of genes. To have a less directed approach in this context, broader 
molecular testing strategies are needed. Whole-exome sequencing 
(WES) analyses the majority of the protein-coding sequences of 
the genome for mutations. In contrast, whole-genome sequencing 
(WGS) analyses the whole genome, recognising that many variants 
that can potentially influence health may lie in regulatory or control 
regions of the genome. These strategies have the potential to detect 
mutations in genes known to be associated with IDD that were not 
clinically suspected, and to allow for new gene discovery. While WES 
has been used in diagnostic practice for a number of years and WGS 
is becoming available as a diagnostic test, these strategies remain 
hampered by the cost and complexity of interpretation, particularly 
in less-well-characterised populations, such as those in Africa. 
However, with diagnostic detection rates of up to 60% in selected 
IDD cases,[16,17] these exome/genome wide approaches are likely to 
become more commonplace in the near future, but will continue to 
require comprehensive clinical correlation.[16]
Interpreting genetic test results
One of the challenges of genetic testing is the extent of normal human 
variation. It can therefore be challenging to determine if a detected 
variant is clinically and functionally significant. This is true for small 
chromosomal copy number changes, as well as variants within genes 
and their regulatory regions. As a result, a genetic test can produce 
three possible outcomes:[11]
• abnormal result with a pathogenic or likely pathogenic variant 
detected
• normal result with no clinically significant variant detected 
• variant/s of uncertain significance detected. 
Variants of uncertain significance cannot be used for decision-
making, as there is insufficient evidence to determine if the change is 
pathogenic or benign. Further evidence (including, possibly, family 
segregation studies and functional analysis) may be needed before 
disease association can be assigned. As evidence accumulates over 
time, including knowledge regarding population-specific variation, 
reclassification of the significance of a variant is possible. This should 
be taken into consideration during longitudinal follow-up of patients 
and families. 
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Conclusion 
Patients with GDD and ID are present in all populations and 
present to healthcare services in all communities. A systematic 
clinical evaluation and appropriate investigations can contribute in 
many ways to improved healthcare for those affected, their families 
and society in general. Knowledge about the value, limitations 
and interpretation of investigations is core to delivering on the 
expectation of improved health and wellbeing that advances in the 
field of medical genetics can bring. 
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